Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 1
2007 6
2008 9
2009 4
2010 6
2011 8
2012 8
2013 11
2014 9
2015 1
2022 1
2023 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Etravirine has no effect on QT and corrected QT interval in HIV-negative volunteers.
Peeters M, Janssen K, Kakuda TN, Schöller-Gyüre M, Lachaert R, Hoetelmans RM, Woodfall B, De Smedt G. Peeters M, et al. Ann Pharmacother. 2008 Jun;42(6):757-65. doi: 10.1345/aph.1K681. Epub 2008 Apr 29. Ann Pharmacother. 2008. PMID: 18445705 Clinical Trial.
The maximum mean (90% CI) difference of time-matched changes in QTcF versus placebo on day 1 was +0.1 msec (-2.6 to 2.9), -0.2 msec (-2.6 to 2.1), and +10.1 msec (7.3 to 12.8) for etravirine 200 mg twice daily, etravirine 400 mg once daily, and moxifloxacin, respect …
The maximum mean (90% CI) difference of time-matched changes in QTcF versus placebo on day 1 was +0.1 msec (-2.6 to 2.9), -0.2 msec (-2.6 to …
Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir.
Song I, Borland J, Min S, Lou Y, Chen S, Patel P, Wajima T, Piscitelli SC. Song I, et al. Antimicrob Agents Chemother. 2011 Jul;55(7):3517-21. doi: 10.1128/AAC.00073-11. Epub 2011 May 9. Antimicrob Agents Chemother. 2011. PMID: 21555764 Free PMC article. Clinical Trial.
Two studies evaluated the effects of etravirine (ETR) alone and in combination with ritonavir (RTV)-boosted protease inhibitors (PIs) on DTG pharmacokinetics (PK) in healthy subjects. ...
Two studies evaluated the effects of etravirine (ETR) alone and in combination with ritonavir (RTV)-boosted protease inhibitors (PIs) …
Pharmacokinetics and pharmacodynamics of etravirine 400 mg once daily in treatment-naive patients.
Di Perri G, Green B, Morrish G, Hill A, Faetkenheuer G, Bickel M, van Delft Y, Kurowski M, Kakuda T. Di Perri G, et al. HIV Clin Trials. 2013 May-Jun;14(3):92-8. doi: 10.1310/hct1403-92. HIV Clin Trials. 2013. PMID: 23835511 Clinical Trial.
Seventy-one subjects had evaluable etravirine pharmacokinetics. The median (interquartile range) of etravirine AUC24h and C0h were 12,447 (8,261-15,652) ngh/mL and 330 (188-472) ng/mL, respectively. There was no correlation between etravirine exposure and vir …
Seventy-one subjects had evaluable etravirine pharmacokinetics. The median (interquartile range) of etravirine AUC24h and C0h …
Pharmacokinetics of elvitegravir and etravirine following coadministration of ritonavir-boosted elvitegravir and etravirine.
Ramanathan S, Kakuda TN, Mack R, West S, Kearney BP. Ramanathan S, et al. Antivir Ther. 2008;13(8):1011-7. Antivir Ther. 2008. PMID: 19195326 Clinical Trial.
Group 1 (n = 20) followed a sequence of 10-day dosing of elvitegravir/r (150/100 mg once daily) and elvitegravir/r plus etravirine (200 mg twice daily) or the reverse (n = 10 per sequence). Group 2 (n = 14) followed a sequence of 10-day dosing of etravirine and e …
Group 1 (n = 20) followed a sequence of 10-day dosing of elvitegravir/r (150/100 mg once daily) and elvitegravir/r plus etravirine (2 …
Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients.
Kakuda TN, Wade JR, Snoeck E, Vis P, Schöller-Gyüre M, Peeters MP, Corbett C, Nijs S, Vingerhoets J, Leopold L, De Smedt G, Woodfall BJ, Hoetelmans RM. Kakuda TN, et al. Clin Pharmacol Ther. 2010 Nov;88(5):695-703. doi: 10.1038/clpt.2010.181. Epub 2010 Sep 29. Clin Pharmacol Ther. 2010. PMID: 20881958 Clinical Trial.
The pharmacokinetics and pharmacodynamics of the antiretroviral agent etravirine were evaluated in two phase III clinical trials. Pharmacokinetic data were available in 577 patients randomized to receive etravirine. ...Virologic response (<50 copies/ml) at week 2 …
The pharmacokinetics and pharmacodynamics of the antiretroviral agent etravirine were evaluated in two phase III clinical trials. Pha …
Pharmacokinetics and short-term safety of etravirine in combination with fluconazole or voriconazole in HIV-negative volunteers.
Kakuda TN, Van Solingen-Ristea R, Aharchi F, Smedt GD, Witek J, Nijs S, Vyncke V, Hoetelmans RM. Kakuda TN, et al. J Clin Pharmacol. 2013 Jan;53(1):41-50. doi: 10.1177/0091270011433329. Epub 2013 Jan 24. J Clin Pharmacol. 2013. PMID: 23400742 Clinical Trial.
Based on least squares means (LSM) ratios, coadministration of etravirine with fluconazole or voriconazole resulted in higher etravirine exposures (area under plasma concentration-time curve from 0-12 hours [AUC(12) (h) ] 1.86- and 1.36-fold, respectively). ...Pharm …
Based on least squares means (LSM) ratios, coadministration of etravirine with fluconazole or voriconazole resulted in higher etra …
Virological response with fully active etravirine: pooled results from the DUET-1 and DUET-2 trials.
Clumeck N, Cahn P, Molina JM, Mills A, Nijs S, Vingerhoets J, Witek J. Clumeck N, et al. Int J STD AIDS. 2010 Nov;21(11):738-40. doi: 10.1258/ijsa.2010.010139. Int J STD AIDS. 2010. PMID: 21187353 Clinical Trial.
The objective of this subanalysis of the Phase III DUET trials was to examine virological response to an etravirine-containing regimen in patients harbouring virus fully sensitive to etravirine. ...At Week 48 in the etravirine group, 74% of patients with e …
The objective of this subanalysis of the Phase III DUET trials was to examine virological response to an etravirine-containing regime …
Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials.
Katlama C, Clotet B, Mills A, Trottier B, Molina JM, Grinsztejn B, Towner W, Haubrich R, Nijs S, Vingerhoets J, Woodfall B, Witek J. Katlama C, et al. Antivir Ther. 2010;15(7):1045-52. doi: 10.3851/IMP1662. Antivir Ther. 2010. PMID: 21041921 Clinical Trial.
RESULTS: In total, 599 patients received etravirine and 604 received placebo. At week 96, 57% of patients in the etravirine group versus 36% in the placebo group had a viral load <50 copies/ml (P<0.0001); 91% and 88% of patients, respectively, had maintained t …
RESULTS: In total, 599 patients received etravirine and 604 received placebo. At week 96, 57% of patients in the etravirine gr …
Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials.
Katlama C, Haubrich R, Lalezari J, Lazzarin A, Madruga JV, Molina JM, Schechter M, Peeters M, Picchio G, Vingerhoets J, Woodfall B, De Smedt G; DUET-1, DUET-2 study groups. Katlama C, et al. AIDS. 2009 Nov 13;23(17):2289-300. doi: 10.1097/QAD.0b013e3283316a5e. AIDS. 2009. PMID: 19710593 Clinical Trial.

RESULTS: Patients (1203) were randomized and treated (n = 599, etravirine; n = 604, placebo). Significantly more patients in the etravirine than in the placebo group achieved viral load less than 50 copies/ml at week 48 (61 vs. 40%, respectively; P < 0.0001). ...

…
RESULTS: Patients (1203) were randomized and treated (n = 599, etravirine; n = 604, placebo). Significantly more patients in the e …
Pharmacokinetic evaluation of the interaction between etravirine and rifabutin or clarithromycin in HIV-negative, healthy volunteers: results from two Phase 1 studies.
Kakuda TN, Woodfall B, De Marez T, Peeters M, Vandermeulen K, Aharchi F, Hoetelmans RM. Kakuda TN, et al. J Antimicrob Chemother. 2014 Mar;69(3):728-34. doi: 10.1093/jac/dkt421. Epub 2013 Oct 23. J Antimicrob Chemother. 2014. PMID: 24155058 Clinical Trial.
Clarithromycin study: 16 participants received 200 mg of etravirine twice daily (commercial formulation; 8 days) and then 500 mg of clarithromycin twice daily (13 days) plus 200 mg of etravirine twice daily (days 6-13). ...Clarithromycin increased etravirine …
Clarithromycin study: 16 participants received 200 mg of etravirine twice daily (commercial formulation; 8 days) and then 500 mg of c …
59 results

Searches related to "etravirine"